Cardio Diagnostics Holdings Inc. announced the availability of Cardio Diagnostics' Epi+Gen CHD test in Idaho. As a result of this partnership, Cardio Diagnostics' Epi+Gen CHD test, which combines epigenetics, genetics, high-throughput computing, and AI to identify those at risk for coronary heart disease, will now be available to eligible patients. Strategic collaborations between forward-thinking provider organizations and innovative biotechnology companies create knowledge-sharing opportunities that can accelerate the adoption of new medical technologies to supplement current practices and positively impact the well-being of patients.

Through this partnership between Healing Sanctuary Clinic and Cardio Diagnostics to make Epi+Gen CHD available to eligible patients in Idaho, the two organizations are excited to address their mutual goal of decreasing the incidence of heart disease among Americans.